Wells Fargo & Company Issues Positive Forecast for Globus Medical (NYSE:GMED) Stock Price

Posted by Francis Steltz on Nov 6th, 2026

Globus Medical (NYSE:GMED – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $99.00 to $100.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 33.35% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Needham & Company LLC decreased their target price on Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday. Truist Financial dropped their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. UBS Group began coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 price objective on the stock. Finally, BMO Capital Markets cut shares of Globus Medical from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $94.00 to $78.00 in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Check Out Our Latest Stock Report on GMED

Globus Medical Stock Performance

Shares of NYSE GMED opened at $74.99 on Friday. The stock has a market cap of $10.07 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.40 and a beta of 0.98. Globus Medical has a fifty-two week low of $72.54 and a fifty-two week high of $101.40. The stock has a fifty day moving average of $77.44 and a 200-day moving average of $83.29.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The firm had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts predict that Globus Medical will post 4.99 EPS for the current year.

Insider Buying and Selling

In related news, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the completion of the sale, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ann Rhoads sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares of the company’s stock, valued at approximately $3,007,640. This represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 60,000 shares of company stock worth $4,838,400 in the last quarter. 18.38% of the stock is owned by insiders.

Institutional Investors Weigh In On Globus Medical

Institutional investors have recently made changes to their positions in the business. Elevation Wealth Partners LLC grew its holdings in shares of Globus Medical by 2,178.6% during the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. Continuum Advisory LLC bought a new stake in Globus Medical in the second quarter worth $25,000. Root Financial Partners LLC bought a new stake in Globus Medical in the third quarter worth $29,000. Heritage Family Offices LLP bought a new stake in Globus Medical in the third quarter worth $31,000. Finally, Jacobi Capital Management LLC purchased a new stake in Globus Medical during the third quarter valued at about $40,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and above $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, potentially supporting shareholder returns. Third-quarter results and repurchase program
Positive Sentiment: Needham lowered its price target from $117 to $100 but maintained a Buy rating. The revised target remains above the cited share price of $81.13. Needham analyst recommendations
Positive Sentiment: The reported acquisition of Synaptive Medical may broaden Globus’s cranial-neurosurgery technology and strengthen its position in that market. Synaptive Medical acquisition
Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38%. One director’s sale does not by itself establish a change in the company’s outlook. Director share sale
Negative Sentiment: Revenue of $763.7 million missed the $792.4 million consensus and fell 0.7% year over year. Full-year revenue guidance of $3.1 billion is below the $3.2 billion analyst estimate, while EPS guidance of $4.95–$5.05 is broadly in line with expectations. Quarterly results and guidance
Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target from $94 to $78, citing a more cautious view of the shares. BMO analyst recommendations

Globus Medical Company Profile

(Get Free Report)

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.